APP and amyloidosis: To test the robustness of FUS-MB across transgenic strains, we repeated the treatment described above in 26 month-old PDAPP mice (n = 2), which express a mutant form of APP that results in severe amyloidosis and accompanying pathology, including neuritic dystrophies, astrocytosis, and microgliosis [15].